Hepatitis Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hepatitis Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Hepatitis B Virus
Investigators at Baylor University release new data on hepatitis B virus
June 15th, 2009
"Alpha interferon is the only licensed drug for hepatitis B with immuno modulatory as well as viral inhibitory properties. Potential advantages of interferon compared to nucleoside analogs include a lack of drug resistance, a finite and defined treatment course, and a higher likelihood for hepatitis B surface antigen (HBsAg) clearance," scientists writing in the journal Hepatology report. "Approximately 30% of hepatitis B e antigen (HBeAg) -positive and 40% of HBeAg-negative cases have a sustained virological response (when defined as HBeAg seroconversion and/or hepatitis B virus (HBV) DNA levels below 20,000 copies/mL, respectively) 6 months after completion of...
Source: Hepatitis Weekly (2009-06-15)
|
